Table 1.
The characteristics of 96 NHL patients
| No. of Patients (%) | |
|---|---|
| Age, years (median, range) | 57, 23-87 |
| Sex | |
| Male | 61 (63.5) |
| Female | 35 (36.5) |
| Histologic type (WHO) | |
| Diffuse large B cell lymphoma | 70 (72.9) |
| Mantle cell lymphoma | 6 (6.2) |
| T cell lineage | 16 (16.7) |
| Follicular lymphoma | 2 (2.1) |
| Burkitt's lymphoma | 2 (2.1) |
| Performance status | |
| 0 | 32 (33.3) |
| 1 | 60 (62.5) |
| 2 | 4 (4.2) |
| Stage | |
| I | 16 (16.7) |
| II | 40 (41.6) |
| III | 18 (18.8) |
| IV | 22 (22.9) |
| Extra-nodal involvement | |
| Absent | 43 (44.8) |
| Present | 57 (55.2) |
| IPI | |
| Low | 52 (54.1) |
| Low-intermediate | 18 (18.8) |
| High-intermediate | 20 (20.8) |
| High | 6 (6.3) |
| Bone marrow involvement | |
| Absent | 90 (93.8) |
| Present | 5 (5.2) |
| Not identified | 1 (1.0) |
| Therapeutic regimen | |
| R-CHOP | 79 (82.3) |
| CHOP | 8 (8.3) |
| Others | 9 (9.4) |
In histologic type, T cell lineage includes anaplastic large cell lymphoma, angioimmunoblastic T cell lymphoma, peripheral T cell lymphoma, and NK/T cell lymphoma. Except of follicular lymphoma as an indolent type of NHL, all other histologic subclasses represent aggressive type.
Performance status was determined according to the criteria, ECOG score.
IPI: international prognostic index
CHOP regimen includes cyclophosphamide, doxorubicin, vincristine, and prednisolone. R-CHOP is a combination regimen of CHOP with the anti-CD20 monoclonal antibody, rituximab.